Motohiro Hirao

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 3

Top Topics

Metastatic Breast Cancer

Placebo Controlled

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Akihito Kawazoe, Noboru Yamamoto, Naotoshi Sugimoto, Hiasto Kawakami, Takashi Oshima, Kensei Yamaguchi, Kaori Hino, Motohiro Hirao, Yukinori Kurokawa, Takeshi Kawakami, Masahiro Tsuda, Hiroki Hara, Shota Kaname, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Kei Muro
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
Akihito Kawazoe, Noboru Yamamoto, Naotoshi Sugimoto, Hiasto Kawakami, Takashi Oshima, Kensei Yamaguchi, Kaori Hino, Motohiro Hirao, Yukinori Kurokawa, Takeshi Kawakami, Masahiro Tsuda, Hiroki Hara, Shota Kaname, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Kei Muro
Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Kohei Shitara, Motohiro Hirao, Satoru Iwasa, Takashi Oshima, Yoshito Komatsu, Akihito Kawazoe, Yasuyoshi Sato, Takuya Hamakawa, Kan Yonemori, Nozomu Machida, Satoshi Yuki, Takuya Suzuki, Shiori Okumura, Takao Takase, Taro Semba, Bob Zimmermann, Angela Teng, Kensei Yamaguchi
Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF): Results From the Advanced Gastric Cancer Expansion Cohort. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)